Pfizer/BioNTech COVID-19 Vaccine Will Miss US Election, Bourla Clarifies
Executive Summary
Pfizer CEO says that an EUA request for its COVID-19 vaccine is unlikely before late November. Analyst calls Pfizer’s development pace an encouraging sign it could be a more nimble company.
You may also be interested in...
Pfizer’s Arms-Length Attitude Toward Operation Warp Speed: Two Views On How It Worked
Pfizer CEO Albert Bourla and HHS deputy chief of staff Paul Mango offer their perspectives in separate interviews promoting new books about the campaign to develop vaccines against COVID-19.
Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity
The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.
A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian
Still a clinical-stage company, Viking is studying promising candidates for both obesity and MASH in Phase II, but may need to prioritize one while partnering the other.